Previous close | 271.25 |
Open | 271.25 |
Bid | 252.75 |
Ask | 255.60 |
Strike | 200.00 |
Expiry date | 2024-06-21 |
Day's range | 271.25 - 271.25 |
Contract range | N/A |
Volume | |
Open interest | 14 |
The Nasdaq hit a new high Tuesday but Target tumbled early Wednesday. Will Nvidia earnings tonight meet lofty hopes?
Eli Lilly is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising test results for a Crohn's treatment.
In Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically significant and clinically meaningful improvements across multiple clinical and endoscopic endpoints at one year with mirikizumab compared to placebo. Data from this study – the first Phase 3 treat-through data reported for an IL23p19 antibody – will be presented at Digestive Disease Week® (DDW), held